NFDI4DS | UHH-SEMS - Publication Details

Ribavirin does not impact health-related quality of life (HRQOL) in patients on Ombitasvir/ Paritaprevir /Ritonavir and dasabuvir at the end of 12-week treatment in Treatment-NaÏve adults with Genotype 1A (GT1A) Chronic Hepatitis C

Ombitasvir Paritaprevir Ritonavir Dasabuvir

DOI: 10.1016/j.jval.2015.03.1316 Publication Date: 2015-05-05T02:12:38Z

Abstract Supplemental Material References Cited by

AUTHORS (6)

Y. Liu

D. Bernstein

L. Larsen

Y. Luo

Y. Xie

T. Juday

ABSTRACT

SUPPLEMENTAL MATERIAL

Coming soon ....

REFERENCES (0)

CITATIONS (0)

EXTERNAL LINKS

OPENAIRE - Products CROSSREF - Publications OPENALEX - Publications

PlumX Metrics

Ribavirin does not impact health-related quality of life (HRQOL) in patients on Ombitasvir/ Paritaprevir /Ritonavir and dasabuvir at the end of 12-week treatment in Treatment-NaÏve adults with Genotype 1A (GT1A) Chronic Hepatitis C

RECOMMENDATIONS

FAIR ASSESSMENT

Coming soon ....

JUPYTER LAB

Coming soon ....